February 19, 2019

Build Biologics Not Barriers

The current trade conflict between the world's biggest economies — the United States and China — has resulted in both countries imposing billions of dollars’ worth of tariffs on each other’s goods. At the time of writing, U.S. and Chinese officials are ...

Continue Reading

February 19, 2019

CMOs on Fire

Recently, contract manufacturers have taken the conventional definition of outsourcing, and set it on fire. Traditionally, CMOs provided capacity reservoirs for pharma companies to tap as needed. For decades, outsourcing to contract manufacturers has ...

Continue Reading

January 11, 2019

CDMO Outsourcing Trends

Outsourcing to Contract Development and Manufacturing Organizations (CDMOs) has been on the rise, driven by increasingly complex drug candidates and the expertise they require, and now, increasingly for regulatory affairs.   Protein forms of an antibody ...

Continue Reading

January 7, 2019

In Vivo Glycan Engineering Via the Mannosidase I Inhibitor (Kifunenesine) Improves Efficacy of Rituximab Manufacture in Nicotiana benthamiana Plants

Introduction Monoclonal antibodies (mAbs) represent the fastest growing class of therapeutics [1,2] and have been especially beneficial in the treatment of cancer [3]. Since the approval of the first anti-cancer monoclonal antibody in 1986 [4], several ...

Continue Reading

September 10, 2018

Plant Derived Rituximab? iBio Inks "Green" Bioreactor Tech Deal in China

According to the agreement, Delaware, US-based iBio will provide process development and manufacturing services at its Texas facility, and will assist CC-Pharming in preparing a site for eventual manufacturing in China. The first project will focus on ...

Continue Reading
1 2 3 4